- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940179
Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography (PSMA-PET)
PSMA-PET: Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography
The purpose of this study is to make non-approved PSMA radioligands available at CHU de Québec - Université Laval, while assessing their safety. Our hypothesis is that all the PSMA PET radioligand are safe, with a very low incidence of adverse events (AEs). The potential clinical impact of PSMA-PET will be explored in our clinical setting.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marie-Christine Dubé, Ph.D.
- Phone Number: 67708 418-525-4444
- Email: marie-christine.dube@crchudequebec.ulaval.ca
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1R2J6
- Recruiting
- CHU de Quebec-Université Laval
-
Principal Investigator:
- Jean-Mathieu Beauregard, MD
-
Contact:
- Marie-Christine Dube, Ph.D.
- Phone Number: 67708 418-525-4444
- Email: marie-christine.dube@crchudequebec.ulaval.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Reception of a procedure request for PSMA-PET
Exclusion Criteria:
- Incapacity to provide informed consent
- Pregnancy, unless there has been a discussion between the participant and a nuclear medicine physician investigator about the potential clinical benefits vs. the potential risks for the fetus, in the context of the participant's medical condition, and that this discussion is documented in the nuclear medicine physician's clinical report.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PSMA-PET
|
Administration of a PSMA tracer for PET |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of Participants with PSMA PET radiopharmaceuticals-Related Adverse Events as Assessed by CTCAE v5.0 .
Time Frame: up to 1 week
|
up to 1 week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean-Mathieu Beauregard, MD, CHU de Quebec (Université Laval)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-4331
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.